Lyell Immunopharma (NASDAQ:LYEL) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Lyell Immunopharma from “Hold” to “Sell,” although the broader analyst consensus remains “Moderate Buy” with an average price target of $40.86.
• LYEL shares opened at $11.96, near their one-year low of $11.47 and well below the one-year high of $45.00. The company has a market capitalization of about $293 million and continues to report significant losses.
• Lyell reported a quarterly loss of $1.92 per share, slightly better than estimates, but generated no revenue and had a negative net margin. Institutional investors and hedge funds own approximately 66.05% of the stock.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report released on Saturday, Wall Street Zen reports.

LYEL has been the subject of a number of other research reports. B. Riley Financial started coverage on Lyell Immunopharma in a research note on Wednesday, July 22nd. They issued a "buy" rating and a $44.00 target price for the company. Zacks Research upgraded Lyell Immunopharma from a "strong sell" rating to a "hold" rating in a research note on Monday, May 18th. Citizens Jmp reissued a "market outperform" rating and issued a $34.00 price objective on shares of Lyell Immunopharma in a report on Monday, June 15th. HC Wainwright reissued a "buy" rating on shares of Lyell Immunopharma in a report on Friday. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Lyell Immunopharma in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Lyell Immunopharma has a consensus rating of "Moderate Buy" and an average price target of $40.86.

Lyell Immunopharma Stock Performance

LYEL stock opened at $11.96 on Friday. Lyell Immunopharma has a one year low of $11.47 and a one year high of $45.00. The firm has a market cap of $293.02 million, a price-to-earnings ratio of -0.93 and a beta of -0.04. The firm has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $17.27.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping analysts' consensus estimates of ($1.94) by $0.02. The business had revenue of $0.00 million for the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative return on equity of 91.62% and a negative net margin of 920,285.25%. As a group, equities analysts predict that Lyell Immunopharma will post -7.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LYEL. AQR Capital Management LLC lifted its holdings in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company's stock valued at $94,000 after acquiring an additional 154,327 shares during the last quarter. Marshall Wace LLP acquired a new stake in Lyell Immunopharma during the second quarter worth $94,000. Bridgeway Capital Management LLC purchased a new stake in Lyell Immunopharma in the second quarter valued at $159,000. BBR Partners LLC purchased a new stake in Lyell Immunopharma in the fourth quarter valued at $210,000. Finally, Walleye Capital LLC acquired a new position in shares of Lyell Immunopharma in the 2nd quarter valued at $258,000. 66.05% of the stock is currently owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company's approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company's pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.